stemcell-bgh

STEMCELL BioTech Wins 2025 Award for Most Promising Cell & Gene Therapy Startup in APAC, Bringing Its Regenerative Medicine Technology to the Global Stage

2025-09-15

News

SINGAPORE, September 10, 2025 — STEMCELL BioTech, a Taiwanese startup specializing in cell therapy and regenerative medicine, has won the “Most Promising Cell & Gene Therapy Startup in APAC” award. Presented on September 10  at the Asia-Pacific Cell & Gene Therapy Excellence Awards 2025, organized by Singapore-based IMAPAC,the award marks another achievement for Taiwan’s biotechnology industry.

 STEMCELL BioTech received the “Most Promising Cell & Gene Therapy Startup in APAC” award at IMAPAC’s Asia-Pacific Cell & Gene Therapy Excellence Awards 2025 on September 10. From left: Dr. ChiaChe Tsai, Vice President of the R&D and Manufacturing Center at STEMCELL BioTech; Lin Shih-Chi, CEO of STEMCELL BioTech; and award presenter Siang-Chueng Koo, Asia-Pacific Director of Innovative Medicine and Quality at Johnson & Johnson. Photo courtesy of IMAPAC.

 

The awards are regarded as one of the Asia-Pacific region’s most influential honors in regenerative medicine, cell and gene therapy, and biopharmaceuticals. They recognize companies for outstanding achievements that drive industry breakthroughs and innovation. The 2025 ceremony was held alongside Cell & Gene Therapy World Asia 2025 and a conference on biologics contract development and manufacturing in Asia. Together, these events attracted more than 300 representatives from leading biotechnology and pharmaceutical companies across Asia. Award recipients also included major contract development and manufacturing organizations (CDMOs), such as Lonza, WuXi AppTec, and FUJIFILM Biotechnologies.

STEMCELL BioTech stood out among startups from multiple countries and won the award for its patented TZX4 stem cell process optimization technology and an innovative research strategy that integrates Traditional Chinese Medicine (TCM) with precision medicine.

STEMCELL BioTech received the “Most Promising Cell & Gene Therapy Startup in APAC” award at IMAPAC’s Asia-Pacific Cell & Gene Therapy Excellence Awards 2025 on September 10. Lin Shih-Chi, CEO of STEMCELL BioTech, gave an interview to international media. Photo courtesy of STEMCELL BioTech.

“This honor recognizes our work and comes with a responsibility. It strengthens our confidence in our research direction as we continue to study neurodegenerative diseases,” said Lin Shih-Chi, CEO of STEMCELL BioTech. “I believe this award will help us advance the research and preparation needed for future clinical trials, expand our presence in Southeast Asia and the broader Asia-Pacific region, and build more collaborations across disciplines. Through continued research and validation, we hope to bring innovative therapies to more patients in need in the future.”

 

Technology Highlights: Patented TZX4 Stem Cell Technology and Personalized Treatment Integrating Precision Medicine

TZX4 is STEMCELL BioTech’s core patented technology for stem cell process optimization. It was developed through years of research by the team led by Dr. Shinn-Zong Lin, a leading neurosurgeon and Superintendent of Hualien Tzu Chi Hospital. Current cell-based research focuses on evaluating how the technology affects stem cell activity, repair potential, and inflammatory responses in nerve cells. This work aims to lay the foundation for further research into neurological diseases and injuries, including Alzheimer’s disease, Parkinson’s disease, stroke, traumatic brain injury, and spinal injury. These studies do not establish therapeutic efficacy in humans. Any future clinical application will require further research and validation.

“Our greatest strength is a research and development strategy grounded in regenerative medicine that brings together precision medicine and expertise across disciplines,” said Dr. ChiaChe Tsai, Vice President of the R&D and Manufacturing Center at STEMCELL BioTech. In addition to developing novel stem cell drugs and conducting exosome research, the company combines knowledge from Traditional Chinese Medicine (TCM) with genetic tools for precision medicine. Its long-term goal is to develop treatment options tailored to individual patients’ needs. Through close collaboration with hospitals and academic institutions, the company is working to validate its research and lay the groundwork for future clinical translation. This interdisciplinary approach, centered on patient needs, was a key factor in the recognition STEMCELL BioTech received from the international judging panel.

STEMCELL BioTech received the “Most Promising Cell & Gene Therapy Startup in APAC” award at IMAPAC’s Asia-Pacific Cell & Gene Therapy Excellence Awards 2025 on September 10. Photo courtesy of STEMCELL BioTech.

 

Global Impact and Future Plans

Looking ahead, STEMCELL BioTech will continue to strengthen its research and development capabilities through three key initiatives:

  1. Accelerating novel stem cell drug development: Focus on clinical trials of novel stem cell drugs for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company aims to develop more innovative treatment options through an integrative treatment strategy that combines precision medicine with expertise across disciplines.
  2. Expanding across the Asia-Pacific region: Establish stem cell manufacturing facilities that meet Good Manufacturing Practice (GMP) standards in Indonesia and across Southeast Asia. These facilities are intended to increase regional capacity for clinical applications and services and strengthen the company’s presence in the Asia-Pacific market.

  3. Deepening international collaboration and advancing commercialization: Work with international healthcare institutions and academic and research organizations to accelerate the clinical translation of products and their entry into international markets. The company also plans to advance clinical trials in Taiwan and other markets, including the United States. It is actively seeking partners worldwide to collaborate on new drug development.